An inhaled pdgf receptor inhibitor for the treatment of pulmonary arterial hyper
Ended Project Grant Awarded Last action
- Award ID
- R44HL102946
- Recipient
-
Pulmokine, Inc. UEI CJAVXCPZUUM9
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,271,635
Award facts
- Assistance listing
- 93.838 Lung Diseases Research
- Completion date
- Originally
- Place of performance
- Rensselaer, NY 12144, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $999,751 | |
| Amendment | $999,482 | |
| Amendment | $5,000 | |
| Amendment | $999,898 | |
| Amendment | $701,052 | |
| Original award | $1,566,452 |
Show all 11
Quick answers
Who received award R44HL102946?
R44HL102946 was awarded to Pulmokine, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2013.
How much is award R44HL102946 worth?
$5,271,635 has been obligated on R44HL102946.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award